The Covid-19 Plasma Boom Is Over. What Did We Learn From It?
The U.S. government invested $800 million in plasma when the country was desperate for Covid-19 treatments. A year later, the program has fizzled. (Source: NYT Health)
Source: NYT Health - April 18, 2021 Category: Consumer Health News Authors: Katie Thomas and Noah Weiland Tags: your-feed-science Antibodies Blood Donation Coronavirus (2019-nCoV) Clinical Trials Government Contracts and Procurement United States Politics and Government American Red Cross Food and Drug Administration Health and Human Services Depa Source Type: news

North Texas researchers develop device that can detect one of COVID's most serious symptoms
The team of researchers are planning clinical trials in patients with various respiratory illness. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 17, 2021 Category: Pharmaceuticals Authors: Kevin Cummings Source Type: news

North Texas researchers develop device that can detect one of COVID's most serious symptoms
The team of researchers are planning clinical trials in patients with various respiratory illness. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 17, 2021 Category: Biotechnology Authors: Kevin Cummings Source Type: news

Short-term results of the combined application of neodymium-doped yttrium aluminum garnet (Nd:YAG) laser and erbium-doped yttrium aluminum garnet (Er:YAG) laser in the treatment of periodontal disease: a randomized controlled trial
ConclusionsThe combined application of Nd:YAG and Er:YAG laser irradiation as an adjunct to conventional non-surgical therapy showed a significant beneficial effect on periodontal treatment results.Clinical relevanceCombined Nd:YAG and Er:YAG laser irradiation could be a useful procedure additionally to conventional non-surgical periodontal therapy to improve periodontal treatment results.  (Source: Dental Technology Blog)
Source: Dental Technology Blog - April 17, 2021 Category: Dentistry Source Type: news

AHA News: Could the Pandemic Help Boost Diversity in Clinical Trials?
FRIDAY, April 16, 2021 (American Heart Association News) -- The pandemic has exposed troubling inequities in the United States that have left Black and Hispanic people at higher risk of dying from COVID-19 – and getting a smaller share of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 16, 2021 Category: General Medicine Source Type: news

Will You Need a Booster Shot of the COVID-19 Vaccine?
When the first COVID-19 vaccines from Pfizer-BioNTech and Moderna were authorized by the U.S. Food and Drug Administration in December 2020, most people breathed a sigh of relief since both shots were shown to be between 94% and 95% effective in protecting from COVID-19 symptoms. But public health experts warned that nobody really knew how long the protection would last, since the longest clinical trials in people only went to a few months. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) and the chief medical advisor to President Joe Biden, suggested that additional booster ...
Source: TIME: Health - April 16, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Experimental antiviral for COVID-19 effective in hamster study
(NIH/National Institute of Allergy and Infectious Diseases) The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from NIH scientists. MK-4482, delivered orally, is now in human clinical trials. Remdesivir, an antiviral drug already approved by the U.S. Food and Drug Administration for use against COVID-19, must be provided intravenously, making its use primarily limited to clinical settings. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2021 Category: Infectious Diseases Source Type: news

Promising results from first-in-humans study of a novel PET radiopharmaceutical
(University of Turku) The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the vascular adhesion protein 1 (VAP-1) that regulates inflammatory cell traffic, is the first radiopharmaceutical that has been developed completely in Finland and has advanced to clinical trials. In the study that started with healthy volunteers, the radiopharmaceutical was found to be well tolerated and safe. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 16, 2021 Category: International Medicine & Public Health Source Type: news

Can the Covid Vaccine Protect Me Against Virus Variants?
Vaccines do a good job of protecting us from coronavirus, but fear and confusion about the rise of variants have muddled the message. Here are answers to common questions. (Source: NYT Health)
Source: NYT Health - April 15, 2021 Category: Consumer Health News Authors: Tara Parker-Pope Tags: Vaccination and Immunization Clinical Trials Preventive Medicine Coronavirus (2019-nCoV) Viruses Johnson & Moderna Inc Pfizer Inc AstraZeneca PLC New England Journal of Medicine Source Type: news

Tempo lands $200M for digital fitness studio, Benchling scores $200M for pharma research platform and other digital health fundings
Also:  Swiss insulin-delivery company CeQur gets $115M, and Medable gains more funds for clinical-trial process.  (Source: mobihealthnews)
Source: mobihealthnews - April 15, 2021 Category: Information Technology Tags: Investing, Business Source Type: news

' Magic Mushroom' Hallucinogen as Good as Antidepressants: Study
THURSDAY, April 15, 2021 -- The magic ingredient in " magic mushrooms " may be at least as effective as standard medication for depression, an early clinical trial suggests. The study of 59 patients with major depression tested the antidepressant... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 15, 2021 Category: General Medicine Source Type: news

Upstate participating in clinical trial to test blood pressure medication to treat symptoms of Alzheimer ’s
Disruptive agitation can be hard for patients, caregivers. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - April 15, 2021 Category: Universities & Medical Training Tags: News Source Type: news

Cardiologist warns about covid vaccine fraud and hyper-inflammatory immune responses caused by the shots
(Natural News) An expert physicist-nuclear cardiologist appeared on a recent episode of Pandemic War Room to warn the public about the dangers of the experimental covid vaccines and to discuss the fundamental fraud that was used to falsely advertise vaccine efficacy. Dr. Richard Fleming has thoroughly studied the clinical trials for the experimental covid vaccines... (Source: NaturalNews.com)
Source: NaturalNews.com - April 15, 2021 Category: Consumer Health News Source Type: news

Trial shows York leishmaniasis vaccine safe and induces immune responses in patients
(University of York) The results of the first clinical trial of a new vaccine for a neglected tropical disease have demonstrated that it is safe and induces immune responses in patients with the infection. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 15, 2021 Category: Infectious Diseases Source Type: news

Johnson & Johnson Statement on CDC Advisory Committee Meeting on Company COVID-19 Vaccine
NEW BRUNSWICK, N.J., April 14, 2021 – The U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) convened today to consider reports of an extremely rare disorder involving blood clots in combination with low platelets observed in a small number of individuals following vaccination with the Johnson & Johnson COVID-19 vaccine. “The safety and well-being of the people who use our products is our number one priority, and we strongly support awareness of the signs and symptoms of this extremely rare event to ensure the correct diagnosis, appropriate treatment an...
Source: Johnson and Johnson - April 15, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Magic mushrooms show promise in treatment for depression, study says
Trial suggests psilocybin combined with psychological therapy is as effective as antidepressant drugMagic mushrooms have a long and rich history. Now scientists say they could play an important role in the future, with their active ingredient a promising treatment for depression.The results from a small, phase two clinical trial have revealed that two doses of psilocybin appears to be as effective as the common antidepressant escitalopram in treating moderate to severe major depressive disorder, at least when combined with psychological therapy.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 14, 2021 Category: Science Authors: Nicola Davis Science correspondent Tags: Depression Medical research Science UK news Psychology Drugs Society Source Type: news

PhRMA member companies share how they are improving clinical trial diversity
As part of the biopharmaceutical industry ’sefforts to improve health outcomes for patients in underserved communities, PhRMA member companies are identifying ways to improve clinical trial diversity and reduce barriers to participation for Black and Brown communities. As these efforts continue to take shape, our industry is developing potential best practices and key learnings that we are excited to share as part of our effort to tackle these challenges head on. (Source: The Catalyst)
Source: The Catalyst - April 14, 2021 Category: Pharmaceuticals Authors: Dr. Freda Lewis-Hall Tags: Health Equity Source Type: news

In quest to interrupt aging, East Bay biotech lands drug, equity deal with Amgen
The company hopes to move into an early-stage clinical trial next year with a drug that could reduce muscle atrophy and increase activity — major attractions for the evolving "aging" drug market. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 14, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Moderna's vaccine is 90% effective at protecting against infection six months after the final dose
New data from the phase III clinical trial showed Moderna was 90% effective at preventing COVID-19 infection six months after the second dose and 95% at preventing severe disease. (Source: the Mail online | Health)
Source: the Mail online | Health - April 14, 2021 Category: Consumer Health News Source Type: news

Diabetes drug shows potential in fighting cancer
(Massachusetts General Hospital) Phenformin, in combination with immunotherapies like PD-1 immune checkpoint inhibitors, shows greater promise than phenformin or metformin alone. A clinical trial is under way at MGH to evaluate the use of phenformin with an inhibitor of the BRAF-mutated gene, present in roughly half of all melanomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2021 Category: Cancer & Oncology Source Type: news

Children and COVID-19 Vaccine Trials: What to Consider Children and COVID-19 Vaccine Trials: What to Consider
Experts from the Infectious Diseases Society of America, including a pediatrician, offer advice for parents considering enrolling their child in a COVID-19 vaccine clinical trial.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - April 13, 2021 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

Johnson & Johnson Statement on COVID-19 Vaccine (Updated)
NEW BRUNSWICK, N.J., April 13, 2021– The safety and well-being of the people who use our products is our number one priority. We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine. The United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA) are reviewing data involving six reported U.S. cases out of more than 6.8 million doses administered. Out of an abundance of caution, the CDC and FDA have recommended a pause in the use of our vaccine. In addition, we have ...
Source: Johnson and Johnson - April 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Health Highlights: April 13, 2021
Drug/Chemo Combo May Help Lung Cancer Patients: Study A combination of the immune-boosting drug Opdivo and chemotherapy appears to benefit some lung cancer patients before surgery, according to a new study. The clinical trial involving about 350... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 13, 2021 Category: General Medicine Source Type: news

NIH trial of anti-CD14 antibody to treat COVID-19 respiratory disease begins
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2021 Category: International Medicine & Public Health Source Type: news

Thirty-six-month clinical evaluation of posterior high-viscosity bulk-fill resin composite restorations in a high caries incidence population: interim results of a randomized clinical trial
ConclusionsThe 36-month clinical performance of high-viscosity BF resin composites was comparable to conventional incremental-filled resin composites. The FDI criteria better presented the restorations ’ clinical success. However, in the case of failure, both criteria provided the same result.Clinical relevanceHigh-viscosity bulk-fill resin composites showed excellent performance after 36 months in a high caries incidence population. It can be considered a simplified alternative restoration method that reduces operating time and minimizes possible operator errors.  (Source: Dental Technology Blog)
Source: Dental Technology Blog - April 13, 2021 Category: Dentistry Source Type: news

Dr Reddy's receives DCGI approval for COVID-19 vaccine Sputnik for restricted emergency use
The company has received the permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act, Dr Reddy's said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 13, 2021 Category: Pharmaceuticals Source Type: news

RDIF expects 50 mn doses a month of Sputnik V vaccine production in India
The Drug Controller General of India (DCGI) on Monday registered the vaccine under the emergency use authorisation procedure, based on results of clinical trials in Russia, as well as positive data of additional Phase III local clinical trials in India conducted in partnership with Dr Reddy's Laboratories. (Source: The Economic Times)
Source: The Economic Times - April 13, 2021 Category: Consumer Health News Source Type: news

HGCO19 vaccine candidate: Gennova starts enrolment for Phase 1/2 human clinical trials
The DBT said it has approved additional funding towards clinical studies of India's first of its kind' mRNA-based COVID-19 vaccine, HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 13, 2021 Category: Pharmaceuticals Source Type: news

Cincinnati Children ’s: Vaccine trial response ‘overwhelming’ as age range drops to 2 and older
Cincinnati Children ’s Hospital has enrolled five children between the ages of 2 and 4 in its latest Pfizer Covid-19 vaccine clinical trial, and one of its top research officials said public response to its efforts thus far has been “overwhelming.” (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 12, 2021 Category: Health Management Authors: Liz Engel Source Type: news

Diversifying clinical trials and fighting disease requires equity and trust
The COVID-19 pandemic has left no person unaffected, but Black Americans have been disproportionately impacted. Black adults are nearlyfour times more likely to be hospitalized from the virus and nearlythree times more likely to die from the virus than their white counterparts. At the same time, recent polls highlight COVID-19 vaccine hesitancy within Black communities. In fact, only one in four Black Americans (24%) plan to get the vaccine compared to other racial and ethnic groups, and Black Americans are significantly trailing invaccination rates. (Source: The Catalyst)
Source: The Catalyst - April 12, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Equity Source Type: news

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Basel, 12 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casirivimab and imdevimab to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), met its primary and key secondary endpoints. It showed that the subcutaneous administration of casirivimab and imdevimab reduced the risk of sym...
Source: Roche Media News - April 12, 2021 Category: Pharmaceuticals Source Type: news

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Basel, 12 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casirivimab and imdevimab to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), met its primary and key secondary endpoints. It showed that the subcutaneous administration of casirivimab and imdevimab reduced the risk of sym...
Source: Roche Investor Update - April 12, 2021 Category: Pharmaceuticals Source Type: news

CNIO scientists discovers a combination therapy for aggressive brain tumors
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * The researchers conducted an in-depth study of resistance to temozolomide, the first-line treatment for glioblastoma, to which many patients cease to respond over time* The combination of temozolomide and dianhydrogalactitol acts synergistically, overcomes this resistance and increases survival in mice with brain tumours* Treatments for glioblastoma have not improved in the last 20 years. The authors argue for the need to translate these results into clinical trials to study whether this combination therapy is also effective in patients with this disease (S...
Source: EurekAlert! - Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: news

C-Path's Alzheimer's Disease Consortium expands data repository
(Critical Path Institute (C-Path)) The Critical Path Institute's Critical Path for Alzheimer's Disease Consortium today announced that it is significantly expanding its Alzheimer's disease patient-level data repository with high-quality contemporary industry clinical trial datasets, focusing on early stages of the disease. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 12, 2021 Category: International Medicine & Public Health Source Type: news

AI and immunotherapy: Taking the next step
(Case Western Reserve University) Researchers from Case Western Reserve University, New York University (NYU), and University Hospitals in Cleveland have been awarded a five-year, $3 million National Cancer Institute grant to develop and apply AI tools for predicting which lung cancer patients will respond to immunotherapy. This is first time they'll test those tools during an ongoing clinical trial, the next step toward their own clinical trials that would allow physicians to apply the tools with participating patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2021 Category: International Medicine & Public Health Source Type: news

South Korean chipmaker bats US FDA approval of its non-invasive glucose monitoring device
The semiconductor player claims success with D-SaLife in a recent clinical trial involving diabetic outpatients. (Source: mobihealthnews)
Source: mobihealthnews - April 12, 2021 Category: Information Technology Tags: Digital Health, Technology Source Type: news

MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021
(University of Texas M. D. Anderson Cancer Center) Researchers at The University of Texas MD Anderson Cancer Center conducted early phase clinical trials that showed promising results for patients with RET fusion-positive cancers, high-grade and low-grade glioma and ovarian cancer. The results for these studies will be presented at the AACR Annual Meeting 2021. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2021 Category: Cancer & Oncology Source Type: news

Personalized cancer vaccine is safe, shows potential benefit against cancer
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2021 Category: Cancer & Oncology Source Type: news

Thomas Carmichael elected to the Association of American Physicians
Dr. S. Thomas Carmichael has been elected to the Association of American Physicians, an honor society recognizing exemplary physician-scientists who contribute to clinical medicine through the pursuit of basic science. The newly elected members for 2021 were recognized at the association ’s annual meeting, which was held virtually April 8–10.Carmichael, UCLA ’s Frances Stark Professor of Neurology, is the chair of theneurology department in the David Geffen School of Medicine at UCLA and co-director of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.In his research, ...
Source: UCLA Newsroom: Health Sciences - April 9, 2021 Category: Universities & Medical Training Source Type: news

Brazilian Health Regulator Anvisa Authorizes Trials for GSK-Medicago COVID Vaccine Brazilian Health Regulator Anvisa Authorizes Trials for GSK-Medicago COVID Vaccine
Brazilian health regulator Anvisa approved on Thursday the beginning of clinical trials in the country for a new COVID vaccine developed by Canada's Medicago and GlaxoSmithKline, Anvisa said in a statement.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 9, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Pandemic Has Put Many Clinical Trials on Hold
FRIDAY, April 9, 2021 -- Fewer clinical trials are being completed during the pandemic, which experts say could affect medical research for decades to come. Previously, it was reported that more than 80% of clinical trials were suspended between... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 9, 2021 Category: General Medicine Source Type: news

Using genetics, researchers identify potential drugs for early treatment of COVID-19
(Veterans Affairs Research Communications) This is about a new study using human genetics that suggests researchers should prioritize clinical trials of drugs that target two proteins to manage COVID-19 in its early stages. Based on their analyses, the researchers call for prioritizing clinical trials of drugs targeting the proteins IFNAR2 and ACE2. The goal is to identify existing drugs, either FDA-approved or in clinical development for other conditions, that can be repurposed for the early management of COVID-19. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 9, 2021 Category: International Medicine & Public Health Source Type: news

NIH Starts Trial Looking at Rare Allergic Reactions to COVID-19 Vaccines
THURSDAY, April 8, 2021 -- A new clinical trial will investigate whether people who are highly allergic or have a mast cell disorder are at higher risk for a sudden allergic reaction to the Moderna or Pfizer COVID-19 vaccines. " The public... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2021 Category: Pharmaceuticals Source Type: news

NIH Starts Trial Looking at Rare Allergic Reactions to COVID Vaccines
THURSDAY, April 8, 2021 -- A new clinical trial will investigate whether people who are highly allergic or have what's known as a mast cell disorder are at higher risk for a sudden allergic reaction to the Moderna or Pfizer COVID-19 vaccines. " The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 8, 2021 Category: General Medicine Source Type: news

Is the U.S. COVID-19 Vaccine Rollout Working? We ’re Not Sure Yet
After four months and 171 million doses of COVID-19 vaccines administered across the U.S., more than a few of us are eager to know: are the shots working? Thus far, available evidence can half-answer that question: The vaccines are working well for those who can get them. As soon as the rollout kicked off, a variety of researchers began conducting what might be considered an unofficial phase 4 clinical trial, monitoring early vaccine recipients among the general public. Several of their studies have found a significant reduction in both the rates of infection and severity of symptoms among vaccinated populations compared t...
Source: TIME: Health - April 8, 2021 Category: Consumer Health News Authors: Chris Wilson Tags: Uncategorized COVID-19 Source Type: news

New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
             Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI ™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progre...
Source: Roche Media News - April 8, 2021 Category: Pharmaceuticals Source Type: news

New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
             Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI ™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progre...
Source: Roche Investor Update - April 8, 2021 Category: Pharmaceuticals Source Type: news

A new treatment for metastatic lung cancer
(University of Colorado Anschutz Medical Campus) A new phase 3 randomized clinical trial overseen by CU Cancer Center member Chad Rusthoven, MD, and Vinai Gondi, MD, from Northwestern University, is testing whether a new treatment approach could result in improved outcomes for patients with small cell lung cancer (SCLC) that has spread to the brain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2021 Category: Cancer & Oncology Source Type: news

Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma
(St. Jude Children's Research Hospital) Results from a collaborative multi-site clinical trial show the success of adding brentuximab vedotin, reducing radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2021 Category: Cancer & Oncology Source Type: news

MHRP launches trial to evaluate IL-15 Agonist as therapy to reduce HIV reservoir
(The U.S. Military HIV Research Program (MHRP)) The U.S. Military HIV Research Program (MHRP) last week launched a Phase 2 clinical trial in Thailand to evaluate an interleukin-15 (IL-15) superagonist administered during acute HIV infection as an experimental therapy to target establishment of the HIV reservoir at a very early stage. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 8, 2021 Category: Infectious Diseases Source Type: news